PUBLISHER: DelveInsight | PRODUCT CODE: 1048730
PUBLISHER: DelveInsight | PRODUCT CODE: 1048730
Dyslipidemia - Epidemiology Forecast to 2032
DelveInsight's 'Dyslipidemia - Epidemiology Forecast - 2032' report delivers an in-depth understanding of the historical and forecasted epidemiology of Dyslipidemia in Portugal, Switzerland, Greece, Turkey, Poland, Netherlands, Belgium, and Austria.
Dyslipidemia: Disease Understanding
Dyslipidemia Overview
Dyslipidemias (defined as raised plasma concentrations of total cholesterol, LDL cholesterol or triglycerides, or a low plasma concentration of HDL cholesterol or a combination of these features) are major risk factors for ischemic heart disease (IHD).
This condition can result from diet, tobacco exposure, or genetics and can lead to cardiovascular disease with severe complications. These lipids are absorbed from the intestines and are carried throughout the body via lipoproteins for energy, steroid production, or bile acid formation. Major contributors to these pathways are cholesterol, low-density lipoprotein cholesterol (LDL-C), triglycerides, and high-density lipoprotein (HDL). An imbalance of these factors, either from organic or nonorganic causes, can lead to dyslipidemia.
It is divided into two types, primary and secondary. Primary dyslipidemia comes through genes, and secondary dyslipidemia is acquired, which is developed from other issues like obesity or diabetes. Hyperlipidemia is often confused with dyslipidemia. Hyperlipidemia is caused when LDL levels are high, but dyslipidemia is caused by blood fats being either low or high. Hyperlipidemia is a major cause of atherosclerosis, and it includes conditions like ischemic cardiovascular issues, coronary heart disease, and peripheral vascular disease.
High cholesterol has no symptoms, and a blood test is the only way to detect it. History is essential in identifying high-risk individuals. Most importantly, social history would include tobacco use or specific details about diet. Past medical history is vital in identifying patients who need primary prevention versus secondary prevention if statin therapy requires initiation. Lastly, family history is vital to identify.
Dyslipidemia: Epidemiology
The dyslipidemia epidemiology division provides insights into the historical and current patient pool, along with the forecast trend for Portugal, Switzerland, Greece, Turkey, Poland, Netherlands, Belgium, and Austria. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and trends, along with assumptions undertaken.
Key Findings
The disease epidemiology covered in the report provides historical and forecasted dyslipidemia epidemiology segmented as the prevalent cases of dyslipidemia, diagnosed cases of dyslipidemia, gender-specific diagnosed cases of dyslipidemia, prevalence of genetic dyslipidemia by types and lipid-specific diagnosed cases. The report includes the prevalent scenario of dyslipidemia in Portugal, Switzerland, Greece, Turkey, Poland, Netherlands, Belgium, and Austria from 2019 to 2032.
Country-wise Dyslipidemia Epidemiology
The epidemiology segment also provides the dyslipidemia epidemiology data and findings across Portugal, Switzerland, Greece, Turkey, Poland, Netherlands, Belgium, and Austria.
Total prevalent cases of dyslipidemia in the emerging markets (Portugal, Switzerland, Greece, Turkey, Poland, Netherlands, Belgium, and Austria) was approximately 83 million cases in 2021.
According to the estimates, Turkey had the most prevalent dyslipidemia in 2021. On the other hand, Portugal had the lowest prevalent population with approximately 3.4 million cases in 2021.
Scope of the Report:
- Dyslipidemia report covers a detailed overview explaining its causes, symptoms and classification, pathophysiology, diagnosis, and treatment patterns.
- Dyslipidemia Epidemiology Report and Model provide an overview of the risk factors and global trends of dyslipidemia in the emerging markets (Portugal, Switzerland, Greece, Turkey, Poland, Netherlands, Belgium, and Austria).
- The report provides insight into the historical and forecasted patient pool of dyslipidemia in Portugal, Switzerland, Greece, Turkey, Poland, Netherlands, Belgium, and Austria.
- The report helps recognize the growth opportunities in the emerging markets concerning the patient population.
- The report assesses the disease risk and burden and highlights the unmet needs of dyslipidemia.
- The report provides the segmentation of the dyslipidemia epidemiology by prevalent cases of dyslipidemia in the emerging markets.
- The report provides the segmentation of the dyslipidemia epidemiology by diagnosed prevalent cases of dyslipidemia in the emerging markets.
- The report provides the segmentation of the dyslipidemia epidemiology by Gender-specific cases of dyslipidemia in emerging markets.
- The report provides the segmentation of the dyslipidemia epidemiology by Prevalence of genetic dyslipidemia by types in emerging markets.
- The report provides the segmentation of the dyslipidemia epidemiology by Lipid-specific cases of dyslipidemia in emerging markets.
Report Highlights:
- 11-year Forecast of Dyslipidemia epidemiology
- Portugal, Switzerland, Greece, Turkey, Poland, Netherlands, Belgium, and Austria Coverage
- Prevalent cases of dyslipidemia
- Diagnosed cases of dyslipidemia
- Gender-specific diagnosed cases of dyslipidemia
- Prevalence of genetic dyslipidemia by types
- Lipid-specific diagnosed cases of dyslipidemia
KOL Views
We interview KOLs and obtain SME's opinions through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the indications.
Key Questions Answered
- What are the major factors that will drive the change in patient population with dyslipidemia in the emerging markets (Portugal, Switzerland, Greece, Turkey, Poland, Netherlands, Belgium, and Austria) during the forecast period (2019-2032)?
- What are the key findings pertaining to dyslipidemia epidemiology across emerging markets, and which country will have the highest number of patients during the forecast period (2019-2032)?
- What would be the total number of patients with dyslipidemia across the emerging markets during the forecast period (2019-2032)?
- At what CAGR is the patient population expected to grow in the emerging markets forecast period (2019-2032)?
- What are the disease risk, burdens, and unmet needs of dyslipidemia?
- What are the currently available treatments for dyslipidemia?
Reasons to buy:
Dyslipidemia Epidemiology report will allow the user to:
- Develop business strategies by understanding the trends shaping and driving the global dyslipidemia market
- Quantify patient populations in the global dyslipidemia market to improve product design, pricing, and launch plans
- Understand the magnitude of the dyslipidemia population by its prevalent cases.
- Understand the magnitude of the dyslipidemia population by its gender-specific cases.
- Understand the magnitude of the dyslipidemia population by its prevalence of genetic dyslipidemia by types.
- Understand the magnitude of the dyslipidemia population by its lipid-specific diagnosed cases of dyslipidemia.
- The dyslipidemia epidemiology report and model were written and developed by Masters and PhD level epidemiologists
- The dyslipidemia epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports the data presented in the report and showcases disease trends over an 11-year forecast period using reputable sources
Key Assessments
- Patient Segmentation
- Disease Risk and Burden
- Risk of disease by the segmentation
- Factors driving growth in a specific patient population
Geographies Covered
- Portugal
- Switzerland
- Greece
- Turkey
- Poland
- Netherlands
- Belgium
- Austria
Study Period: 2019-2032.
Table of Contents
1. Key Insights
2. Report Introduction
3. Dyslipidemia Epidemiology Overview at a Glance
- 3.1. Patient Share (%) Distribution of Dyslipidemia in 2019
- 3.2. Patient Share (%) Distribution of Dyslipidemia in 2032
4. Executive Summary of Dyslipidemia
5. Disease Background and Overview
- 5.1. Introduction
- 5.2. Classification
- 5.3. Signs and Symptoms
- 5.4. Etiology
- 5.5. Pathogenesis
- 5.6. Diagnosis
6. Epidemiology and Patient Population
- 6.1. Key Findings
- 6.2. Total Prevalent Cases of Dyslipidemia in the Emerging Markets
- 6.3. Assumptions and Rationale
- 6.4. Portugal
- 6.4.1. Prevalent Cases of Dyslipidemia in Portugal
- 6.4.2. Diagnosed Cases of Dyslipidemia in Portugal
- 6.4.3. Gender-specific Diagnosed Cases of Dyslipidemia in Portugal
- 6.4.4. Prevalence of Genetic Dyslipidemia by Types in Portugal
- 6.4.5. Lipid-specific Diagnosed Cases in Portugal
- 6.5. Switzerland
- 6.5.1. Prevalent Cases of Dyslipidemia in Switzerland
- 6.5.2. Diagnosed Cases of Dyslipidemia in Switzerland
- 6.5.3. Gender-specific Diagnosed Cases of Dyslipidemia in Switzerland
- 6.5.4. Prevalence of Genetic Dyslipidemia by Types in Switzerland
- 6.5.5. Lipid-specific Diagnosed Cases in Switzerland
- 6.6. Greece
- 6.6.1. Prevalent Cases of Dyslipidemia in Greece
- 6.6.2. Diagnosed Cases of Dyslipidemia in Greece
- 6.6.3. Gender-specific Diagnosed Cases of Dyslipidemia in Greece
- 6.6.4. Prevalence of Genetic Dyslipidemia by Types in Greece
- 6.6.5. Lipid-specific Diagnosed Cases in Greece
- 6.7. Turkey
- 6.7.1. Prevalent Cases of Dyslipidemia in Turkey
- 6.7.2. Diagnosed Cases of Dyslipidemia in Turkey
- 6.7.3. Gender-specific Diagnosed Cases of Dyslipidemia in Turkey
- 6.7.4. Prevalence of Genetic Dyslipidemia by Types in Turkey
- 6.7.5. Lipid-specific Diagnosed Cases in Turkey
- 6.8. Poland
- 6.8.1. Prevalent Cases of Dyslipidemia in Poland
- 6.8.2. Diagnosed Cases of Dyslipidemia in Poland
- 6.8.3. Gender-specific Diagnosed Cases of Dyslipidemia in Poland
- 6.8.4. Prevalence of Genetic Dyslipidemia by Types in Poland
- 6.8.5. Lipid-specific Diagnosed Cases in Poland
- 6.9. Netherlands
- 6.9.1. Prevalent Cases of Dyslipidemia in the Netherlands
- 6.9.2. Diagnosed Cases of Dyslipidemia in the Netherlands
- 6.9.3. Gender-specific Diagnosed Cases of Dyslipidemia in the Netherlands
- 6.9.4. Prevalence of Genetic Dyslipidemia by Types in the Netherlands
- 6.9.5. Lipid-specific Diagnosed Cases in the Netherlands
- 6.10. Belgium
- 6.10.1. Prevalent Cases of Dyslipidemia in Belgium
- 6.10.2. Diagnosed Cases of Dyslipidemia in Belgium
- 6.10.3. Gender-specific Diagnosed Cases of Dyslipidemia in Belgium
- 6.10.4. Prevalence of Genetic Dyslipidemia by Types in Belgium
- 6.10.5. Lipid-specific Diagnosed Cases in Belgium
- 6.11. Austria
- 6.11.1. Prevalent Cases of Dyslipidemia in Austria
- 6.11.2. Diagnosed Cases of Dyslipidemia in Austria
- 6.11.3. Gender-specific Diagnosed Cases of Dyslipidemia in Austria
- 6.11.4. Prevalence of Genetic Dyslipidemia by Types in Austria
- 6.11.5. Lipid-specific Diagnosed Cases in Austria
7. Patient Journey
8. KOL Views
9. Appendix
- 9.1. Bibliography
- 9.2. Report Methodology
10. DelveInsight Capabilities
11. Disclaimer
12. About DelveInsight
List of Tables
- Table 1: Summary of Dyslipidemia: Epidemiology (2019-2032)
- Table 2: Genetic classification of Dyslipidemia
- Table 3: The Criteria for Diagnosis of Dyslipidemia
- Table 4: Total Diagnosed Prevalent Population of Dyslipidemia in 000's (2019-2032)
- Table 5: Prevalent Cases of Dyslipidemia in Portugal in 000's (2019-2032)
- Table 6: Diagnosed Cases of Dyslipidemia in Portugal in 000's (2019-2032)
- Table 7: Gender-specificspecific Diagnosed Cases of Dyslipidemia in Portugal (2019-2032)
- Table 8: Prevalence of Genetic Dyslipidemia by Types in Portugal (2019-2032)
- Table 9: Lipid-specific Diagnosed Cases in Portugal (2019-2032)
- Table 10: Prevalent Cases of Dyslipidemia in Switzerland in 000's (2019-2032)
- Table 11: Diagnosed Cases of Dyslipidemia in Switzerland in 000's (2019-2032)
- Table 12: Gender-specific Diagnosed Cases of Dyslipidemia in 000's in Switzerland (2019-2032)
- Table 13: Prevalence of Genetic Dyslipidemia by Types in Switzerland (2019-2032)
- Table 14: Lipid-specific Diagnosed Cases in Switzerland (2019-2032)
- Table 15: Prevalent Cases of Dyslipidemia in Greece in 000's (2019-2032)
- Table 16: Diagnosed Cases of Dyslipidemia in Greece in 000's (2019-2032)
- Table 17: Gender-specific Diagnosed Cases of Dyslipidemia in Greece (2019-2032)
- Table 18: Prevalence of Genetic Dyslipidemia by Types in Greece (2019-2032)
- Table 19: Lipid-specific Diagnosed Cases in Greece (2019-2032)
- Table 20: Prevalent Cases of Dyslipidemia in 000's Turkey (2019-2032)
- Table 21: Diagnosed Cases of Dyslipidemia in Turkey in 000's (2019-2032)
- Table 22: Gender-specific Diagnosed Cases of Dyslipidemia in Turkey in 000's (2019-2032)
- Table 23: Prevalence of Genetic Dyslipidemia by Types in Turkey (2019-2032)
- Table 24: Lipid-specific Diagnosed Cases in Turkey in 000's (2019-2032)
- Table 25: Prevalent Cases of Dyslipidemia in 000's Poland (2019-2032)
- Table 26: Diagnosed Cases of Dyslipidemia in Poland in 000's (2019-2032)
- Table 27: Gender-specific Diagnosed Cases of Dyslipidemia in 000's Poland (2019-2032)
- Table 28: Prevalence of Genetic Dyslipidemia by Types in Poland (2019-2032)
- Table 29: Lipid-specific Diagnosed Cases in 000's Poland (2019-2032)
- Table 30: Prevalent Cases of Dyslipidemia in the Netherlands in 000's (2019-2032)
- Table 31: Diagnosed Cases of Dyslipidemia in the Netherlands in 000's (2019-2032)
- Table 32: Gender-specific Diagnosed Cases of Dyslipidemia in Netherlands 000's (2019-2032)
- Table 33: Prevalence of Genetic Dyslipidemia by Types in Netherlands 000's (2019-2032)
- Table 34: Lipid-specific Diagnosed Cases in the Netherlands in 000's (2019-2032)
- Table 35: Prevalent Cases of Dyslipidemia in Belgium in 000's (2019-2032)
- Table 36: Diagnosed Cases of Dyslipidemia in Belgium 000's (2019-2032)
- Table 37: Gender-specific Diagnosed Cases of Dyslipidemia in Belgium in 000's (2019-2032)
- Table 38: Prevalence of Genetic Dyslipidemia by Types in Belgium (2019-2032)
- Table 39: Lipid-specific Diagnosed Cases in Belgium in 000's(2019-2032)
- Table 40: Prevalent Cases of Dyslipidemia in Austria in 000's (2019-2032)
- Table 41: Diagnosed Cases of Dyslipidemia in Austria in 000's (2019-2032)
- Table 42: Gender-specific Diagnosed Cases of Dyslipidemia in Austria in 000's (2019-2032)
- Table 43: Prevalence of Genetic Dyslipidemia by Types in Austria (2019-2032)
- Table 44: Lipid-specific Diagnosed Cases in Austria in 000's (2019-2032)
List of Figures
- Figure 1: Dyslipidemic states
- Figure 2: Classification of Dyslipidemia
- Figure 3: Eyelid Xanthelasmas
- Figure 4: Tendinous xanthomas at the Achilles
- Figure 5: Xanthomas over back
- Figure 6: Causes of Dyslipidemia
- Figure 7: Total Prevalent Cases of Dyslipidemia in the Emerging Markets in 000's (2019-2032)
- Figure 8: Prevalent Cases of Dyslipidemia in 000's in Portugal (2019-2032)
- Figure 9: Diagnosed Cases of Dyslipidemia in 000's in Portugal (2019-2032)
- Figure 10: Gender-specific Diagnosed Cases of Dyslipidemia in Portugal in 000's (2019-2032)
- Figure 11: Prevalence of Genetic Dyslipidemia by Types in Portugal in 000's (2019-2032)
- Figure 12: Lipid-specific Diagnosed Cases in Portugal in 000's (2019-2032)
- Figure 13: Prevalent Cases of Dyslipidemia in Switzerland in 000's (2019-2032)
- Figure 14: Diagnosed Cases of Dyslipidemia in Switzerland in 000's (2019-2032)
- Figure 15: Gender-specific Diagnosed Cases of Dyslipidemia in Switzerland in 000's (2019-2032)
- Figure 16: Prevalence of Genetic Dyslipidemia by Types in Switzerland in 000's (2019-2032)
- Figure 17: Lipid-specific Diagnosed Cases in Switzerland in 000's (2019-2032)
- Figure 18: Prevalent Cases of Dyslipidemia in Greece in 000's (2019-2032)
- Figure 19: Diagnosed Cases of Dyslipidemia in Greece in 000's (2019-2032)
- Figure 20: Gender-specific Diagnosed Cases of Dyslipidemia in Greece in 000's (2019-2032)
- Figure 21: Prevalence of Genetic Dyslipidemia by Types in Greece in 000's (2019-2032)
- Figure 22: Lipid-specific Diagnosed Cases in Greece in 000's (2019-2032)
- Figure 23: Prevalent Cases of Dyslipidemia in Turkey in 000's (2019-2032)
- Figure 24: Diagnosed Cases of Dyslipidemia in Turkey in 000's (2019-2032)
- Figure 25: Gender-specific Diagnosed Cases of Dyslipidemia in Turkey in 000's (2019-2032)
- Figure 26: Prevalence of Genetic Dyslipidemia by Types in Turkey in 000's (2019-2032)
- Figure 27: Lipid-specific Diagnosed Cases in Turkey in 000's (2019-2032)
- Figure 28: Prevalent Cases of Dyslipidemia in Poland in 000's (2019-2032)
- Figure 29: Diagnosed Cases of Dyslipidemia in Poland in 000's (2019-2032)
- Figure 30: Gender-specific Diagnosed Cases of Dyslipidemia in Poland in 000's (2019-2032)
- Figure 31: Prevalence of Genetic Dyslipidemia by Types in Poland in 000's (2019-2032)
- Figure 32: Lipid-specific Diagnosed Cases in Poland in 000's (2019-2032)
- Figure 33: Prevalent Cases of Dyslipidemia in the Netherlands in 000's (2019-2032)
- Figure 34: Diagnosed Cases of Dyslipidemia in the Netherlands in 000's (2019-2032)
- Figure 35: Gender-specific Diagnosed Cases of Dyslipidemia in the Netherlands in 000's (2019-2032)
- Figure 36: Prevalence of Genetic Dyslipidemia by Types in the Netherlands in 000's (2019-2032)
- Figure 37: Lipid-specific Diagnosed Cases in the Netherlands in 000's (2019-2032)
- Figure 38: Prevalent Cases of Dyslipidemia in Belgium in 000's (2019-2032)
- Figure 39: Diagnosed Cases of Dyslipidemia in Belgium in 000's (2019-2032)
- Figure 40: Gender-specific Diagnosed Cases of Dyslipidemia in Belgium in 000's (2019-2032)
- Figure 41: Prevalence of Genetic Dyslipidemia by Types in Belgium in 000's (2019-2032)
- Figure 42: Lipid-specific Diagnosed Cases in Belgium in 000's (2019-2032)
- Figure 43: Cases of Dyslipidemia in Austria in 000's (2019-2032)
- Figure 44: Diagnosed Cases of Dyslipidemia in Austria in 000's (2019-2032)
- Figure 45: Gender-specific Diagnosed Cases of Dyslipidemia in Austria in 000's (2019-2032)
- Figure 46: Prevalence of Genetic Dyslipidemia by Types in Austria in 000's (2019-2032)
- Figure 47: Lipid-specific Diagnosed Cases in Austria in 000's (2019-2032)
